Background {#Sec1}
==========

Increasing evidence demonstrates that excess visceral fat locates upstream of the metabolic syndrome, a cluster of diabetes, dyslipidemia, and hypertension, which is associated with atherosclerotic cardiovascular diseases \[[@CR1]\]. In a series of clinical studies, we have shown that visceral fat area (VFA), but not subcutaneous fat area (SFA), correlates significantly and strongly with cardio-metabolic diseases \[[@CR2], [@CR3]\]. Various groups, including ours, have focused on the underlying molecular mechanism and links between visceral fat accumulation and cardio-metabolic diseases \[[@CR4], [@CR5]\]. Some of the discussed molecular pathological links between visceral adiposity and cardio-metabolic diseases include dysregulation of adipocytokines \[[@CR1]\], chronic low-grade inflammation of visceral fat tissue \[[@CR6]\], and harmful changes in gut microbiota \[[@CR7]\]. However, the exact mechanism(s) remains unresolved.

We have also examined the role of gene expression profile in peripheral blood cells, and reported that visceral adiposity can alter the expression profiles of various genes in peripheral blood cells, including those involved in circadian rhythm and inflammation \[[@CR8], [@CR9]\]. However, in these studies, visceral adiposity, including VFA and SFA, was not assessed by modern precision technology such as computed tomography (CT). In addition, impact of SFA on gene expressions in peripheral blood cells was not determined. Moreover, most of the enrolled subjects were overt type 2 diabetes patients (HbA1c; 8.1 ± 2.2%) in our previous study \[[@CR8], [@CR9]\], suggesting that gene expression profile in peripheral blood cells influenced by these parameters. Other groups also investigated the impact of VFA and/or SFA on the expression of various genes in peripheral blood cells. For example, Lee et al. \[[@CR10]\] found a significant association between VFA, but not SFA, and sirtuin 1 (SIRT1) mRNA level in peripheral blood mononuclear cells.

The aim of the present study was to define the association of VFA and SFA determined by CT, with the gene expression profile in peripheral blood cells in obese subjects free of overt diabetes.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The enrolled subjects were hospitalized at Sumitomo Hospital between February 2012 and April 2014 to receive calorie-restricted diet therapy for obesity. Subjects with type 1 diabetes mellitus, cancer, autoimmune diseases, and infectious diseases were excluded from the present study. Patients treated with glucose-lowering agents were also excluded. Written informed consent was obtained from each patient after explaining the purpose of study. The study protocol was approved by the human ethics committees of Sumitomo Hospital and Osaka University. The study was also registered with the University Hospital Medical Information Network (UMIN \#000001663).

Clinical parameters {#Sec4}
-------------------

Obesity was defined as body mass index (BMI) greater than 25 kg/m^2^ according to the criteria of the Japan Society for the Study of Obesity \[[@CR11]\]. VFA and SFA were measured on the cross-sectional CT slice at the umbilical level \[[@CR12]\]. Waist circumference was measured with a tape at the umbilical level in standing position. Serum adiponectin concentration was measured by a latex particle-enhanced turbidimetric immunoassay with a human adiponectin latex kit (Otsuka Pharmaceutical Co., Tokyo, Japan). The homeostasis model − assessment of insulin resistance (HOMA-IR) was calculated by the equation: \[HOMA-IR = fasting insulin (µU/mL) × fasting glucose (mg/dL)/405\]. Type 2 diabetes mellitus and borderline diabetes were defined according to the criteria of the Japan Diabetes Society \[[@CR13]\]. Briefly, diabetes was defined as fasting glucose of ≥126 mg/dL, casual glucose of ≥200 mg/dL, or HbA1c of ≥6.5%. Hypertension was defined as systolic blood pressure (SBP) of ≥140 mm Hg, diastolic BP (DBP) of ≥90 mm Hg, or treatment with anti-hypertensive agents. Dyslipidemia was defined as fasting triglycerides (TG) of ≥150 mg/dL, high-density lipoprotein cholesterol (HDL-C) of \<40 mg/dL, or low-density lipoprotein cholesterol (LDL-C) of ≥140 mg/dL, or treatment with lipid-lowering agents. LDL-C was calculated using the Friedewald formula, except in cases with TG of \>400 mg/dL. The estimated glomerular filtration rate (eGFR) was calculated by using the following formula: \[eGFR = 194 × (serum creatinine^−1.094^) × (age^−0.287^) × F (male, F = 1; female, F = 0.739)\] \[[@CR14]\]. Intima-media thickness (IMT) of common carotid artery was measured by echography (HI VISION Preirus; Hitachi, Tokyo).

Microarray analysis {#Sec5}
-------------------

Blood samples were collected into PaxGene Blood RNA tubes (PreAnalytiX, Qiagen Inc., Valencia, CA) before breakfast and left to stand for 2 h at room temperature. The tubes were kept at −20 °C for 2 days and then stored at −80 °C. Total RNA was extracted from the blood sample by using PaxGene Blood RNA Kit (PreAnalytiX, Qiagen). After RNA was qualified by Agilent 2100 Bioanalyzer, 100 ng of total RNA was converted to cDNA, amplified, and labeled with Cy3-labeled CTP using the Quick Amp Labeling kit (Agilent Technologies, Santa Clara, CA). The amplified cRNA and dye incorporation were quantified using ND-1000 Spectrophotometer (Nano Drop Technologies, Wilmington, DE) and hybridized to SurePrint G3 Human GE Microarray 8 × 60 k ver. 2.0 (Design ID: 039494, Agilent Technologies). After hybridization, arrays were washed consecutively by using Gene Expression Wash Pack (Agilent Technologies). Fluorescence images of the hybridized arrays were generated using the Agilent DNA Microarray Scanner, and the intensities were extracted with Agilent Feature Extraction software ver. 10.7.3.1. The raw microarray data are deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO Series GSE85226).

Microarray data analyses {#Sec6}
------------------------

The raw microarray intensities were processed by the percentile shift method (75th percentile) with GeneSpring GX 13.0 (Agilent Technologies) so as to normalize the range of expression intensities for inter-microarray. Genes found to be expressed in more than 50% of the hybridizations were subjected to further analyses. The normalized data were exported from the GeneSpring GX software. The univariate correlation between clinical parameters, including VFA and SFA, and peripheral blood gene expression levels was examined by Pearson's correlation under the R environment (<http://cran.at.r-project.org>). Gene ontology (GO) information was retrieved from the annotations in GeneSpring GX 13.0.

Results {#Sec7}
=======

Characteristics of the enrolled subjects {#Sec8}
----------------------------------------

The clinical characteristics of the participating subjects are listed in Table [1](#Tab1){ref-type="table"}. The mean BMI and waist circumference were 30.0 kg/m^2^ (range, 24.0--44.0 kg/m^2^) and 101.2 cm (range, 85--127 cm), respectively. The mean VFA and SFA were 177.3 cm^2^ (range, 78--318 cm^2^) and 244.7 cm^2^ (range, 80--558 cm^2^), respectively. The mean serum adiponectin concentration was 4.2 μg/mL (range, 2.3--9.8 μg/mL) and the mean HbA1c was 6.3% (range, 5.3--10.9%). Among the 17 subjects, 5 had type 2 diabetes, 6 had borderline diabetes, and 6 subjects had normal glucose tolerance. All 5 diabetic patients were not treated with any anti-diabetic agents. Atherosclerotic plaque in the carotid artery (IMT ≥1.1 mm) was observed in 7 subjects. Among the 17 subjects, dyslipidemia and hypertension were found in 15 and 8 subjects, respectively. Seven patients were treated with statins and four patients were treated with angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB).Table 1Characteristics of subjectsN17Sex (male/female)14/3Age (years)54.6 ± 14.6BMI (kg/m^2^)30 ± 5.5Waist circumference (cm)101 ± 11Visceral fat area (cm^2^)177 ± 67Subcutaneous fat area (cm^2^)245 ± 131Adiponectin (μg/mL)4.2 ± 1.7Systolic blood pressure (mm Hg)132 ± 17Diastolic blood pressure (mm Hg)82 ± 13.7Fast plasma glucose (mg/dL)102 ± 21Hemoglobin A1c (%)6.3 ± 1.3Diagnosis (T2DM/B/N)5/6/6HOMA-IR3.2 ± 2.3Total cholesterol (mg/dL)206 ± 40Triglyceride (mg/dL)196 ± 129HDL-C (mg/dL)56.3 ± 18.1LDL-C (mg/dL)114 ± 40Uric acid (mg/dL)6.4 ± 0.8Urinary albumin (μg/day)12.3 ± 10.6eGFR (mL/min/1.73 m^2^)77.9 ± 19.8mean IMT ≥1.1 mm7/10Statin use (±)7/10ACE-I/ARB use (±)4/13Data are mean ± SD*T2DM* type 2 diabetes mellitus, *B* borderline diabetes, *N* normal glucose tolerance, *HOMA*-*IR* homeostasis model assessment of insulin resistance, *HDL*-*C* high density lipoprotein-cholesterol, *LDL*-*C* low density lipoprotein-cholesterol, *eGFR* estimated glomerular filtration rate, *IMT* intima-media thickness, *ACE*-*I* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blocker

Gene expression profiles {#Sec9}
------------------------

Peripheral blood RNA samples were subjected to microarray analysis. The target probes were selected under the condition that significant signals were detected in more than 7 cases among 17 subjects and thus 23,197 probes were extracted for gene expression analysis. Table [2](#Tab2){ref-type="table"} lists the number of probes that showed significant changes according to various clinical variables under the statistical environment that the parametric false discovery rate (FDR) was less than 0.1. Sex and age had impacts on 52 and 625 probes, respectively. Surprisingly, VFA had a great impact on peripheral blood cells gene expression, i.e., 1354 probes consisting of 307 up-regulated and 1047 down-regulated probes. However, no significant gene probes were detected with SFA or BMI. Serum adiponectin, diabetes, HbA1c, and HOMA-IR also had no impact on the gene expression in peripheral blood cells. Likewise, statins and ACE-I/ARB had no effect. Figure [1](#Fig1){ref-type="fig"} illustrates the number of upregulated/downregulated probes according to various clinical parameters. Table [3](#Tab3){ref-type="table"} lists the top 30 genes that correlated significantly with VFA positively and negatively. Among these genes, Krüppel-like factor 10 (KLF10) was the most significant (Table [3](#Tab3){ref-type="table"}).Table 2Changes in probes according to various clinical parametersFDR \< 0.1UpDown*Categorical*Sex522032Diagnosis of diabetes000Mean IMT000Statin use000ACE-I/ARB use000*Continuous*Age625206419Body mass index000Visceral fat area13543071047Subcutaneous fat area000Adiponectin000Hemoglobin A1c000HOMA-IR000Data represent number of probes*FDR* false discovery rate, *IMT* intima-media thickness, *ACE*-*I* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blocker, *HOMA*-*IR* homeostasis model assessment of insulin resistance Fig. 1Changes in the number of genes according to various clinical parameters. The target 23,197 probes were selected under the condition that significant signals were detected in more than 7 cases among 17 subjects. Data represent the number of probes that showed significant upregulation and downregulation according to the listed clinical parameters under the statistical environment that the parametric false discovery rate (FDR) was less than 0.1. Parameters such as sex, diagnosis for diabetes, mean IMT, statin use, and ACE-I/ARB use were adopted as categorical variables. Age, BMI, visceral and subcutaneous fat areas, adiponectin, hemoglobin A1c, and HOMA-IR were adopted as continuous variables. *BMI* body mass index; *HOMA-IR* homeostasis model assessment of insulin resistance; *IMT* intima-media thickness; *ACE-I* angiotensin converting enzyme inhibitor; *ARB* angiotensin II receptor blocker Table 3Top 30 genes that correlated positively and negatively with visceral fat areaProbe nameGene symbolGene nameR*p* valueFDR*Positive correlation*A_21_P0013668SPATA31C2SPATA31 subfamily C, member 20.8303.72E−050.08430563A_19_P00803850LOC100505474Uncharacterized LOC1005054740.8284.01E−050.08430563A_33_P3238410SBF1SET binding factor 10.8146.93E−050.08430563A_23_P325676ZNF653Zinc finger protein 6530.8031.03E−040.08430563A_23_P384532CCDC11Coiled-coil domain containing 110.8021.07E−040.08430563A_33_P3311956FEZ2Fasciculation and elongation protein zeta 2 (zygin II)0.8011.13E−040.08430563A_23_P430670CHST5Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 50.7971.29E−040.08430563A_33_P3253653GPR155G protein-coupled receptor 1550.7792.29E−040.08430563A_33_P3314974PARD6G-AS1PARD6G antisense RNA 10.7782.33E−040.08430563A_33_P34027730.7752.61E−040.084956675A_24_P117942TOMM20LTranslocase of outer mitochondrial membrane 20 homolog (yeast)-like0.7712.94E−040.084956675A_33_P3772937KRT8P12Keratin 8 pseudogene 120.7683.15E−040.084956675A_33_P34048890.7683.20E−040.084956675A_33_P3379436FAM74A4Family with sequence similarity 74, member A40.7673.29E−040.084956675A_23_P34066IL9RInterleukin 9 receptor0.7653.50E−040.084956675A_23_P417415ACOT11Acyl-CoA thioesterase 110.7584.19E−040.084956675A_33_P3410093LTA4HLeukotriene A4 hydrolase0.7584.22E−040.084956675A_33_P3334895GRIN2AGlutamate receptor, ionotropic, N-methyl D-aspartate 2A0.7505.26E−040.084956675A_23_P72697GPIHBP1Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 10.7495.40E−040.084956675A_33_P3378531AS3MTArsenite methyltransferase0.7485.57E−040.084956675A_24_P75190HBDHemoglobin, delta0.7475.76E−040.084956675A_23_P26457HBA2Hemoglobin, alpha 20.7446.08E−040.084956675A_33_P32658660.7446.09E−040.084956675A_21_P0004859BTN2A1Butyrophilin, subfamily 2, member A10.7416.63E−040.084956675A_21_P0005185DKFZp686L13185Uncharacterized LOC4012870.7396.95E−040.084956675A_21_P0012204XLOC_0145120.7397.00E−040.084956675A_21_P0009476XLOC_0126700.7377.45E−040.084956675A_33_P3365932WASH1WAS protein family homolog 10.7347.91E−040.084956675A_19_P00812257LINC01191Long intergenic non-protein coding RNA 11910.7328.26E−040.084956675A_23_P209564CYBRD1Cytochrome b reductase 10.7328.36E−040.084956675*Negative correlation*A_23_P168828KLF10KRUPPEL-like factor 10−0.8561.16E−050.08430563A_32_P54544CCT6AChaperonin containing TCP1, subunit 6A (zeta 1)−0.8323.40E−050.08430563A_23_P389919WHSC1Wolf-Hirschhorn syndrome candidate 1−0.8303.74E−050.08430563A_23_P44139PRIM2Primase, DNA, polypeptide 2 (58 kDa)−0.8274.21E−050.08430563A_19_P00331853LOC100131564uncharacterized LOC100131564−0.8264.34E−050.08430563A_23_P501877ZFP64ZFP64 zinc finger protein−0.8264.36E−050.08430563A_24_P3973HNRNPA2B1Heterogeneous nuclear ribonucleoprotein A2/B1−0.8264.46E−050.08430563A_23_P215088ZC3HC1Zinc finger, C3HC-type containing 1−0.8264.47E−050.08430563A_23_P7679NUP155Nucleoporin 155 kDa−0.8166.50E−050.08430563A_33_P3381483ZNF331Zinc finger protein 331−0.8117.73E−050.08430563A_23_P115149WDR77WD repeat domain 77−0.8088.71E−050.08430563A_23_P151093YARS2Tyrosyl-tRNA synthetase 2, mitochondrial−0.8078.92E−050.08430563A_23_P251421CDCA7Cell division cycle associated 7−0.8078.94E−050.08430563A_21_P0008290LINC00641Long intergenic non-protein coding RNA 641−0.8079.17E−050.08430563A_33_P3262665MAP7D3MAP7 domain containing 3−0.8059.59E−050.08430563A_33_P3213557CCZ1CCZ1 vacuolar protein trafficking and biogenesis associated homolog (*S. cerevisiae*)−0.8059.60E−050.08430563A_23_P202143NOLC1Nucleolar and coiled-body phosphoprotein 1−0.8041.01E−040.08430563A_23_P46924BUB3BUB3 mitotic checkpoint protein−0.8031.04E−040.08430563A_24_P925635SEPT7P2Septin 7 pseudogene 2−0.8031.06E−040.08430563A_24_P345822TFGTRK-fused gene−0.8021.08E−040.08430563A_23_P85180TMEM187Transmembrane protein 187−0.8011.10E−040.08430563A_33_P3221234IPPIntracisternal A particle-promoted polypeptide−0.8011.13E−040.08430563A_33_P3415037VDAC2Voltage-dependent anion channel 2−0.7991.20E−040.08430563A_33_P3309929HDAC3Histone deacetylase 3−0.7991.21E−040.08430563A_23_P214798SYNCRIPSynaptotagmin binding, cytoplasmic RNA interacting protein−0.7961.34E−040.08430563A_21_P0012709XLOC_014512−0.7951.38E−040.08430563A_24_P116909MALT1Mucosa associated lymphoid tissue lymphoma translocation gene 1−0.7941.42E−040.08430563A_23_P69437YEATS2YEATS domain containing 2−0.7931.45E−040.08430563A_33_P3251538MAPKAP1Mitogen-activated protein kinase associated protein 1−0.7931.46E−040.08430563A_23_P102202MSH6Muts homolog 6−0.7931.47E−040.08430563

Gene ontology {#Sec10}
-------------

Gene ontology (GO) analysis was also performed to further determine the impact of VFA on gene expression profile in peripheral blood cells. As shown in Table [4](#Tab4){ref-type="table"}, visceral fat adiposity correlated significantly with genes related to the metabolic process, oxygen transport, and nucleotide binding. Genes involved in inflammation (GO: 0006954), oxidative stress (GO: 0006979), immune response (GO: 0006955), lipid metabolism (GO: 0006629), and glucose metabolism (GO: 0006006), were finally examined. Figure [2](#Fig2){ref-type="fig"} shows the percentage of genes (among all genes) that correlated significantly with SFA and VFA (*p* \< 0.05). VFA correlated with 17.6, 26.8, 18.4, 25.5, and 26.4% of genes involved in inflammation, oxidative stress, immune response, lipid metabolism, and glucose metabolism, respectively, while the respective percentages for SFA were only 4.2, 2.6, 2.7, 3.4, and 3.2%.Table 4Significant GO terms based on genes that correlated positively and negatively with visceral fat areaGOGO termCorrected *p* value*Positive correlation*Biological processOxygen transport8.821E−04Gas transport3.707E−03Molecular functionOxygen transporter activity5.310E−04Cellular componentHemoglobin complex3.428E−04*Negative correlation*Biological processRNA processing6.559E−21Heterocycle metabolic process1.252E−20Cellular nitrogen compound metabolic process8.348E−20Nucleobase-containing compound metabolic process1.702E−19Organic cyclic compound metabolic process2.892E−19Cellular aromatic compound metabolic process6.642E−19Cellular metabolic process4.940E−18Nitrogen compound metabolic process9.293E−18Nucleic acid metabolic process1.052E−16Cellular macromolecule metabolic process1.780E−16Metabolic process1.122E−14Primary metabolic process1.551E−14Gene expression3.068E−14Organic substance metabolic process7.768E−14Macromolecule metabolic process1.529E−11RNA metabolic process3.440E−11mRNA processing5.194E−11ncRNA metabolic process1.859E−10RNA splicing5.494E−10Molecular functionRNA binding1.470E−10Nucleotide binding2.106E−07Nucleoside phosphate binding2.143E−07Heterocyclic compound binding1.144E−06Nucleic acid binding2.081E−06Aminoacyl-tRNA ligase activity2.924E−06Ligase activity, forming aminoacyl-tRNA and related compounds2.924E−06Ligase activity, forming carbon--oxygen bonds2.924E−06Organic cyclic compound binding3.035E−06Small molecule binding3.265E−06Catalytic activity1.736E−04ATP-dependent helicase activity3.046E−04Purine NTP-dependent helicase activity3.046E−04Structure-specific DNA binding3.201E−04ATPase activity9.197E−04ATPase activity, coupled1.738E−03Adenyl nucleotide binding1.738E−03ATP binding1.799E−03Adenyl ribonucleotide binding2.557E−03Cellular componentNuclear part2.984E−28Intracellular part6.115E−28Intracellular1.984E−27Intracellular membrane-bounded organelle8.017E−27Membrane-enclosed lumen6.105E−24Intracellular organelle lumen6.201E−24Nuclear lumen6.172E−23Organelle lumen8.194E−23Intracellular organelle part2.042E−22Intracellular organelle2.087E−22Membrane-bounded organelle1.535E−21Organelle part3.743E−21Nucleus1.105E−20Organelle1.383E−17Nucleolus2.194E−16Nucleoplasm4.535E−15Mitochondrion1.779E−13Mitochondrial part1.863E−09Cytoplasm2.197E−09 Fig. 2Percentages of obesity-related genes that correlated significantly with visceral and subcutaneous fat area. Gene ontology analysis was performed to examine the impact of visceral fat area (VFA) and subcutaneous fat area (SFA) on the percentage of obesity-associated genes (relative to total number of genes), such as inflammation (GO:0006954), oxidative stress (GO:0006979), immune response (GO:0006955), lipid metabolism (GO:0006629), and glucose metabolism (GO:0006006)

Discussion {#Sec11}
==========

The major finding of the present study was that visceral fat, but not subcutaneous fat, in obese individuals had a significant impact on peripheral blood cells gene expression profile. While similar results were reported previously by our group \[[@CR8], [@CR9]\], these studies had several limitations: (1) VFA was estimated by abdominal bioelectrical impedance analysis (BIA), rather than by CT. The latter is recognized as the gold standard method for fat area measurement \[[@CR12], [@CR15], [@CR16]\]. (2) The majority of the subjects enrolled in the above previous studies were diabetics (75%) with a mean HbA1c of 8.1%. The inclusion of such patients could have influenced the results. (3) Impact of SFA on gene expression level in peripheral blood cells could not be determined under abdominal BIA procedure. The present study is clinically more significant as it included precise measurement of VFA and SFA by CT scan and negligible diabetic conditions.

The biological differences between visceral and subcutaneous fat have been investigated. The rate of lipolysis and lipogenesis activities are higher in adipocytes of visceral fat tissue than those of subcutaneous fat tissue \[[@CR17], [@CR18]\], suggesting that visceral fat accumulation increases free fatty acids (FFA) in the portal vein, accelerates hepatic lipogenesis, and results in dyslipidemia involving high FFA level in the bloodstream. Visceral fat accumulation also enhances inflow of glycerol into the liver and hepatic glucose production through adipose and hepatic glycerol channels; aquaporin 7 and 9, respectively \[[@CR19]\]. Furthermore, adipose mRNA levels dynamically change in visceral fat compared to subcutaneous fat, especially in obese subjects. As BMI increases, the mRNA levels of adiponectin and peroxisome proliferator-activated receptor gamma (PPARγ) are reduced, while mRNA level of NADPH oxidase subunit p22, promoting reactive oxygen species (ROS), is augmented, in visceral fat, but not in subcutaneous fat \[[@CR20]\]. Visceral fat accumulation is also a major risk for the reduction of circulating adiponectin (hypoadiponectinemia) \[[@CR1]\]. Collectively, compared to subcutaneous fat, visceral fat accumulation largely and pathologically alters not only its own fat tissue, but also circulating substances and metabolic outcome. It is therefore conceivable that these visceral fat-mediated changes can also alter the gene expression profile in peripheral blood cells.

Increasing evidence indicates that chronic low-grade inflammation in the adipose tissue, especially in visceral fat, is located upstream of the metabolic syndrome \[[@CR21], [@CR22]\]. Gut microbiota also accelerates inflammatory changes in visceral fat \[[@CR7]\]. Various immune cells infiltrate adipose tissue and cause inflammatory changes through direct cell--cell interaction and/or indirect cytokine-mediated intercellular communication. It is not hard to imagine that such interactions among immune cells and adipocytes influence peripheral blood cells, but such processes have not been confirmed yet. The present study also suggests that gene expression profile of peripheral blood cells reflects local inflammatory changes in visceral fat.

Interestingly, KLF10, a member of the Krüppel-like family of transcription factors, showed the most significant and negative correlation with VFA (Table [3](#Tab3){ref-type="table"}). KLF10 is augmented through the transforming growth factor-β (TGF-β)-Smad signaling pathway \[[@CR23]\]. It plays a crucial role in TGF-β-mediated induction of regulatory T-cells (Treg) from naive T-cells \[[@CR24]\]. In mice lacking KLF10, Treg activity was reduced and proinflammatory changes were accelerated. Transfer of KLF10-deficient T-cells failed to suppress the development of atherosclerosis in apolipoprotein E knockout mice with high-fat diet \[[@CR25]\]. KLF10-deficient mice also showed hyperglycemia in males and hypertriglyceridemia in females \[[@CR26]\]. KLF10 has been shown to regulate 20--30% of hepatic genes related to glucose and lipid metabolism \[[@CR26]\]. Genetic variants of KLF10 are associated with susceptibility to type 2 diabetes \[[@CR27]\]. However, KLF10 mRNA expressions were not significantly correlated with diabetes or dyslipidemia in present study. To confirm the association between KLF10 expressions in peripheral blood cells and diabetes or dyslipidemia, further investigations would be desired in some other populations, different from present clinical profiles, such as non-obese or non-diabetic subjects. Present data provides a possibility that visceral fat adiposity-associated reduction in peripheral blood KLF10 mRNA level is related to the pathogenesis of the metabolic syndrome, although further clinical studies would be needed in future.

The present study has several limitations. The study population was small and the proportion of female was low. Several participants received medications such as statins and ACE-I/ARBs. Importantly, the majority of subjects were obese and showed abundant accumulation of visceral fat according to the Japanese criteria; the study included only one subject with VFA below 100 cm^2^. The full impact of VFA on the gene expression profile of peripheral blood cells has not been determined previously and should be examined also in non-obese individuals. In the present study, among the top 30 genes that correlated positively with VFA (Table [3](#Tab3){ref-type="table"}), 14 (46.7%) genes were up-regulated in obesity, and among the top 30 genes that correlated negatively with VFA (Table [3](#Tab3){ref-type="table"}), 17 (56.7%) genes were down-regulated in obesity. Unfortunately, a control group of non-obese subjects could not be included in the present study for ethical reasons (exposure of such subjects to CT scanning). For this reason, no data are available for the correlation of VFA and SFA to the gene expression profile of peripheral blood cells in non-obese subjects. Therefore, our results can only be applied to obese individuals.

Conclusions {#Sec12}
===========

The present study demonstrated that accumulation of visceral fat, but not that of subcutaneous fat, alters the gene expression profile of peripheral blood cells in obese Japanese subjects. The results should enhance our understanding of the pathogenesis of the metabolic syndrome.

NM, YY, KY, SN, MY, TF, KM, and YM designed the study. YO, YY, KY, and YM contributed blood samples. YO, NM, and SN performed the statistical analysis. MY, YT, SM, HN, SF, YF, SK, and HN contributed to the discussion. YO, NM, and SN drafted the manuscript, and YY, KY, TF, KM, YM, and IS edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

We thank Kayoko Ohashi from the Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, for the excellent technical assistance. We also thank all members of the III^rd^ Laboratory (Adiposcience Laboratory), Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, and Department of Endocrinology and Metabolism, Sumitomo Hospital, for the helpful discussion on the project.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.

Availability of data and material {#FPar3}
=================================

The raw microarray data are deposited at the National Center for Biotechnology Information Gene Expression Omnibus (GEO Series GSE85226).

Ethics approval and consent to participate {#FPar4}
==========================================

Written informed consent was obtained from each patient after explaining the purpose of study. The study protocol was approved by the human ethics committees of Sumitomo Hospital and Osaka University. This study was also registered with the University hospital Medical Information Network (UMIN \#000001663).

Funding {#FPar5}
=======

This work was supported in part by the Japan Society for the Promotion of Science (JSPS)-Grants-in-Aid for Scientific Research (KAKENHI) \#JP25461386 (to NM), \#JP16K09782 (to MY) and \#JP26293221 (to TF), Takeda Science Foundation (to NM), and Japan Foundation for Applied Enzymology (to YF). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
